Jiangsu Hengrui Gains NMPA Clinical Clearance for HRS-9821 in COPD Treatment
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clinical clearance...
Company
Boston Scientific’s FARAPULSE Gains FDA Approval for Expanded Use in Persistent Atrial Fibrillation
US-based Boston Scientific Corporation (NYSE: BSX) announced that it has received US FDA approval for...
HutchMed Announces First Commercial Shipments of Tazverik Across China
China-based HutchMed (NASDAQ: HCM, HKG: 0013) announced the first commercial shipments of Tazverik (tazemetostat) across...
Shenzhen Concemed Medtech Secures Hundreds of Millions in Series A+ Funding for Endoscopy Expansion
Shenzhen Concemed Medical Technology Co., Ltd., a China-based endoscope specialist, has reportedly secured “hundreds of...
RemeGen Submits New Indication Application for Disitamab Vedotin in Urothelial Carcinoma
RemeGen Ltd (HKG: 9995) announced that the National Medical Products Administration (NMPA) in China has...
Grand Pharma’s SIR-Spheres Y-90 Gets FDA Accelerated Approval for Unresectable HCC
China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced that SIR-Spheres Y-90 resin microspheres (SIR-Spheres), a...
Boehringer Ingelheim Starts Phase III THULITE Study for BI 1815368 in Diabetic Macular Edema
German pharmaceutical major Boehringer Ingelheim announced the initiation of the Phase III THULITE study to...
GSK Completes Acquisition of Boston Pharma’s BP Asset IX for Efimosfermin Alpha
UK-based GlaxoSmithKline (GSK; NYSE: GSK) announced the completion of its acquisition of BP Asset IX, a...
Qilu Pharmaceutical Partners with Sagent Pharmaceuticals to Expand US Market Presence
China-based Qilu Pharmaceutical Co., Ltd. this week announced a strategic partnership with US-headquartered Sagent Pharmaceuticals....
Roche’s Chugai Pharmaceutical Partners with Gero to Develop Therapies for Age-Related Diseases
Roche’s Japan-based subsidiary Chugai Pharmaceutical Co., Ltd. (TYO: 4519) announced this week a joint research...
CStone Pharmaceuticals Licenses Cejemly to Istituto Gentili for 23 Countries in Europe and the UK
China-based CStone Pharmaceuticals (HKG: 2616) announced a licensing agreement with Istituto Gentili S.R.L., granting the...
Jiangsu CTTQ’s TQB2102 Receives Breakthrough Therapy Designation for HER2+ Breast Cancer
Subsidiary of China based Sino Biopharmaceutical Ltd (HKG: 1177) Jiangsu Chia Tai Tianqing Pharmaceutical Co.,...
Wepon Medical Receives NMPA Clinical Approval for WP107 in Generalized Myasthenia Gravis
Wepon Medical Holding Group Co., Ltd. (SHE: 002082) announced that it has received clinical approval...
SCG Cell Therapy Obtains NMPA Approval for SCG101V in Chronic HBV Study
China’s Center for Drug Evaluation of the National Medical Products Administration (NMPA) has approved SCG...
BGI Genomics Launches Mini Breast Cancer 76-Gene Detection System for Personalized Treatment
China-based BGI Genomics Co., Ltd (SHE: 300676) announced the launch of its mini breast cancer...
AstraZeneca’s Imfinzi Approved in EU for Perioperative Treatment of Muscle-Invasive Bladder Cancer
UK-based AstraZeneca (AZ, NASDAQ: AZN) announced that it has received marketing approval in the European...
Modella AI Collaborates with AstraZeneca to Accelerate Oncology Drug Development with AI
US-based Modella AI, a leader in biomedical artificial intelligence (AI), announced a multi-year collaboration with...
CStone Pharmaceuticals Announces Phase III Trial Progress for Nofazinlimab in Hepatocellular Carcinoma
China-based CStone Pharmaceuticals (HKG: 2616) announced the latest progress in its global multicenter Phase III...
Micot Raises Over RMB 100 Million in Series D Funding Led by Zheshang Venture Capital
Micot, a polypeptide new molecular entity (NME) drug developer with operations in mainland China, Hong...
AstraZeneca in Talks for $15B Licensing Deal for Ivonescimab with Summit Therapeutics
UK-based AstraZeneca plc (AZ, NASDAQ: AZN) is reportedly in negotiations with Summit Therapeutics, the US...